Overview

CONSHOHOCKEN, Pa. , May 08, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: “Madrigal continued to make significant progress in the first quarter of 2019, initiating a Phase 3 study of MGL-3196

-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at 36 weeks --        -- The data suggest that reduction of hepatic fat is a critical component of

-- Investigator meeting held March 21/22, 2019 -- -- In Phase 2 study resmetirom was statistically significantly superior to placebo in resolving NASH on biopsy, appeared safe and was well-tolerated -- CONSHOHOCKEN, Pa. , March 28, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.